178 related articles for article (PubMed ID: 34238767)
61. Colectomy rate in acute severe ulcerative colitis in the infliximab era.
Aratari A; Papi C; Clemente V; Moretti A; Luchetti R; Koch M; Capurso L; Caprilli R
Dig Liver Dis; 2008 Oct; 40(10):821-6. PubMed ID: 18472316
[TBL] [Abstract][Full Text] [Related]
62. Surgical management of ulcerative colitis in the presence of primary sclerosing cholangitis.
Poritz LS; Koltun WA
Dis Colon Rectum; 2003 Feb; 46(2):173-8. PubMed ID: 12576890
[TBL] [Abstract][Full Text] [Related]
63. Colectomy rate in ulcerative colitis 15 years after diagnosis: Results from the 2001-2003 Navarra cohort.
Rodríguez C; Elosua A; Prieto C; Pérez E; Irisarri R; Campillo A; Rubio S; Nantes Ó; Angós R; Zozaya JM
Gastroenterol Hepatol; 2022 Jan; 45(1):1-8. PubMed ID: 33545242
[TBL] [Abstract][Full Text] [Related]
64. Long-term effects and colectomy rates in ulcerative colitis patients treated with infliximab: a Danish single center experience.
Teisner AS; Ainsworth MA; Brynskov J
Scand J Gastroenterol; 2010 Dec; 45(12):1457-63. PubMed ID: 20701434
[TBL] [Abstract][Full Text] [Related]
65. Epidemiology and clinical characteristics of ulcerative colitis in Chinese population: experience from a single center in Hong Kong.
Lok KH; Hung HG; Ng CH; Kwong KC; Yip WM; Lau SF; Li KK; Li KF; Szeto ML
J Gastroenterol Hepatol; 2008 Mar; 23(3):406-10. PubMed ID: 17623033
[TBL] [Abstract][Full Text] [Related]
66. Ulcerative colitis in China: retrospective analysis of 3100 hospitalized patients.
Wang Y; Ouyang Q;
J Gastroenterol Hepatol; 2007 Sep; 22(9):1450-5. PubMed ID: 17716349
[TBL] [Abstract][Full Text] [Related]
67. Treatment and outcome of ulcerative colitis during the first 10 years after diagnosis in a prospectively followed population-based cohort.
Rönnblom A; Karlbom U
Scand J Gastroenterol; 2021 Apr; 56(4):403-409. PubMed ID: 33577739
[TBL] [Abstract][Full Text] [Related]
68. Prevalence and Risk Factors for Therapy Escalation in Ulcerative Colitis in the Swiss IBD Cohort Study.
Safroneeva E; Vavricka SR; Fournier N; Straumann A; Rogler G; Schoepfer AM
Inflamm Bowel Dis; 2015 Jun; 21(6):1348-58. PubMed ID: 25806845
[TBL] [Abstract][Full Text] [Related]
69. [Ulcerative pancolitis predicts the need for colectomy: study of an incident cohort of patients with ulcerative colitis in Aragón (Spain)].
Sicilia B; Vicente R; Arroyo MT; Arribas F; Gomollón F
Gastroenterol Hepatol; 2005 Feb; 28(2):55-9. PubMed ID: 15710082
[TBL] [Abstract][Full Text] [Related]
70. Infliximab versus Cyclosporine Treatment for Severe Corticosteroid-Refractory Ulcerative Colitis: A Korean, Retrospective, Single Center Study.
Kim EH; Kim DH; Park SJ; Hong SP; Kim TI; Kim WH; Cheon JH
Gut Liver; 2015 Sep; 9(5):601-6. PubMed ID: 25473080
[TBL] [Abstract][Full Text] [Related]
71. Clinical course and predictors of total colectomy in ulcerative colitis; a referral center experience from Turkey.
Kalkan İH; Dağlı Ü; Kekilli M; Öztaş E; Tunç B; Ülker A
Turk J Gastroenterol; 2015 Jan; 26(1):25-30. PubMed ID: 25698267
[TBL] [Abstract][Full Text] [Related]
72. Progression of low-grade dysplasia to advanced neoplasia based on the location and morphology of dysplasia in ulcerative colitis patients with extensive colitis under colonoscopic surveillance.
Navaneethan U; Jegadeesan R; Gutierrez NG; Venkatesh PG; Hammel JP; Shen B; Kiran RP
J Crohns Colitis; 2013 Dec; 7(12):e684-91. PubMed ID: 23916526
[TBL] [Abstract][Full Text] [Related]
73. Efficacy and safety of tacrolimus in refractory ulcerative colitis and Crohn's disease: a single-center experience.
Benson A; Barrett T; Sparberg M; Buchman AL
Inflamm Bowel Dis; 2008 Jan; 14(1):7-12. PubMed ID: 17879277
[TBL] [Abstract][Full Text] [Related]
74. Comparison of Real-World Outcomes of Infliximab versus Adalimumab in Biologic-Naïve Korean Patients with Ulcerative Colitis: A Population-Based Study.
Han M; Jung YS; Cheon JH; Park S
Yonsei Med J; 2020 Jan; 61(1):48-55. PubMed ID: 31887799
[TBL] [Abstract][Full Text] [Related]
75. Adalimumab Maintenance Treatment in Ulcerative Colitis: Outcomes by Prior Anti-TNF Use and Efficacy of Dose Escalation.
Taxonera C; Iglesias E; Muñoz F; Calvo M; Barreiro-de Acosta M; Busquets D; Calvet X; Rodríguez A; Pajares R; Gisbert JP; López-Serrano P; Pérez-Calle JL; Ponferrada Á; De la Coba C; Bermejo F; Chaparro M; Olivares D; Alba C; Fernández-Blanco I
Dig Dis Sci; 2017 Feb; 62(2):481-490. PubMed ID: 27995400
[TBL] [Abstract][Full Text] [Related]
76. Baseline risk assessment of patients with ulcerative colitis: does initial treatment selection influence outcomes?
Mosli M; Alfaer S; Almalaki T; Albeshry A; Aljehani S; Alshmrani B; Habib Z; Jawa H; Qari Y
Eur J Gastroenterol Hepatol; 2019 Jan; 31(1):80-85. PubMed ID: 30199472
[TBL] [Abstract][Full Text] [Related]
77. Demography and clinical course of ulcerative colitis in a multiracial Asian population: a nationwide study from Malaysia.
Hilmi I; Singh R; Ganesananthan S; Yatim I; Radzi M; Chua AB; Tan HJ; Huang S; Chin KS; Menon J; Goh KL
J Dig Dis; 2009 Feb; 10(1):15-20. PubMed ID: 19236542
[TBL] [Abstract][Full Text] [Related]
78. The characteristics of pediatric ulcerative colitis with primary sclerosing cholangitis: A single-center study in Taiwan.
Chien MM; Chang MH; Chang KC; Chiu YC; Chen HL; Hsu HY; Wu JF
Pediatr Neonatol; 2021 Sep; 62(5):483-490. PubMed ID: 34074613
[TBL] [Abstract][Full Text] [Related]
79. Prevalence of corticosteroids use and disease course after initial steroid exposure in ulcerative colitis.
Khan N; Abbas A; Williamson A; Balart L
Dig Dis Sci; 2013 Oct; 58(10):2963-9. PubMed ID: 23812861
[TBL] [Abstract][Full Text] [Related]
80. Proximal colorectal dysplasia or cancer in ulcerative colitis. The impact of primary sclerosing cholangitis and sulfasalazine: results from a 20-year surveillance study.
Lindberg BU; Broomé U; Persson B
Dis Colon Rectum; 2001 Jan; 44(1):77-85. PubMed ID: 11805567
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
